Ezintsha | Wits Health Consortium

Research site

(Unclaimed)

Location

32 Princess of Wales Terrace Building C, Ground Floor, Johannesburg, Guateng, South Africa

Site insights

Top conditions

Top treatments

Doravirine

Islatravir

Paxlovid

Molnupiravir

Semaglutide

VIR-7832

Azithromycin

Baloxavir Marboxil

Rifampicin

Anakinra

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 10 total trials

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and hu...

Active, not recruiting

Human Metapneumovirus

Respiratory Syncytial Virus

Biological: Placebo

Biological: mRNA-1345

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

The safety and tolerability of MK-8591A, a 2-drug fixed dose combination (FDC) of doravirine (DOR 100mg) and islatravir (ISL 0.75mg) will be evaluate...

Active, not recruiting

HIV-1 Infection

Drug: MK-8591A

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) (ESSENCE)

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabe...

Enrolling

Non-alcoholic Steatohepatitis

Drug: Placebo

Drug: Semaglutide

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

This is a phase 3, randomized, controlled, double-blind, multisite clinical study of a once-daily fixed dose combination (FDC) of 100 mg doravirine/0...

Active, not recruiting

HIV-1 Infection

Drug: BIC/FTC/TAF

Drug: DOR/ISL

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus...

Enrolling

HIV-1-infection

Drug: Stable Baseline Regimen

Drug: Bictegravir

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms